ClinicalTrials.gg
CompletedNCT00517530Updated Oct 11, 2016Results posted

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

A Phase 1/2 interventional study of Obinutuzumab in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-11.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Lymphoma by Hoffmann-La Roche — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma · Hoffmann-La Roche.

Enrollment
6th of 15
134 · median 96
Started
2007
with 1 other
Phase 1/2
4 of 17
none open now
Registered
3rd of 17
by date

Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2007, is one of 4 in phase 1/2, and was the 3rd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 17 studies in Lymphoma by Hoffmann-La Roche is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in participants with CD20+ (tumor-infiltrating lymphocytic) Malignant Disease, including B-cell chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). The primary objective for the phase II part of the study is to investigate the efficacy and safety of one dose of obinutuzumab in participants with relapsed/refractory CLL and NHL that is, in turn, either indolent (iNHL) or aggressive (aNHL).

It is an open label dose escalating study in phase I and open label in phase II, but the two doses in iNHL \& aNHL are randomized (to high or low dose of the same open label treatment). CLL was not randomized as only one dose level was used.

Participants with a response who might gain additional benefit from being treated again in the opinion of the investigator may be enrolled in a Retreatment Period.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >=18 years of age;
  • Phase 1 only: CD20+ malignant disease (B-cell lymphoma or B-CLL);
  • Phase 2 only: indolent NHL, relapsed or refractory aggressive NHL or relapsed or refractory B-CLL
  • Have a clinical indication for treatment as determined by the investigator
  • (ECOG) performance status of 0 to 2
  • >12 weeks

Exclusion criteria

Exclusion Criteria:

  • Prior use of any antibody therapy or other agent within 6 months of study start;
  • Prior use of any anti-cancer vaccine;
  • Prior use of standard anti-lymphoma/leukemia therapy or radiation therapy within 4 weeks of enrollment;
  • Prior use of MabThera (rituximab) within 8 weeks of study entry;
  • Prior administration of radioimmunotherapy 3 months prior to study entry;
  • Central nervous system (CNS) lymphoma.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Phase I, NHL

    Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.

    Drug: Obinutuzumab

  • Experimental
    Phase I, CLL

    Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.

    Drug: Obinutuzumab

  • Experimental
    400/400 mg - Phase II, iNHL

    Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.

    Drug: Obinutuzumab

  • Experimental
    1600/800 mg - Phase II, iNHL

    Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.

    Drug: Obinutuzumab

  • Experimental
    400/400 mg - Phase II, aNHL

    Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.

    Drug: Obinutuzumab

  • Experimental
    1600/800 mg - Phase II, aNHL

    Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.

    Drug: Obinutuzumab

  • Experimental
    1000/1000 mg - Phase II, CLL

    Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.

    Drug: Obinutuzumab

  • Experimental
    Retreated Participants

    Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.

    Drug: Obinutuzumab

Interventions

  • Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

    Also known as: RO5072759, GA101

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study

    Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.

    Time frame: Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)

  2. Percentage of Participants With Best Overall Response in Phase II of the Study

    Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)

    Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)

Secondary outcomes

  1. Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study

    A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.

    Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)

  2. Percentage of Participants With Partial Response (PR) in Phase II of the Study

    A PR was defined as a \>=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by \>=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.

    Time frame: by Cutoff Date: 31 March 2012 (within 3 years, 4 months)

  3. Progression-free Survival (PFS) in Phase II of the Study

    PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.

    Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)

  4. Duration of Response by Disease Type in Phase II of the Study

    Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.

    Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)

  5. Participants With Event-Free Survival (EFS) in Phase II of the Study

    EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.

    Time frame: by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)

  6. Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study

    B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.

    Time frame: by the end of Phase II (within 3 years, 4 months)

  7. Percentage of Retreated Participants With Response

    Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.

    Time frame: by Cutoff Date: 25 November 2013 (within 4 years, 2 months)

  8. Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants

    Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.

    Time frame: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)

  9. Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study

    Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.

    Time frame: Day 1 of Cycle 1

Other outcomes

  1. Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients

    Time frame: at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)

07

Results

Posted Sep 22, 2015
Limitations and caveats
Pharmacodynamic results were limited because number of participants was inversely proportional to length of follow-up. In other words, there were fewer participants still in the trial as the follow-up period became longer.

Participant flow

Different patients were recruited into Phase I and Phase II, and analyzed separately based on their disease. In this adaptive trial design, some of those same patients were included in follow-up even if they did not complete treatment, and 13 who had initially responded to treatment but subsequently progressed were retreated.

Participant flow — Overall Study
Milestone50-2000 mg Phase I, NHL400-2000 mg Phase I, CLL400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
Started21131822211920
Completed treatment111313189913
Started follow-up20131721171619
Completed follow-up2001001
Retreated population2214220
Completed2001101
Not completed19131821201919

Outcome measures

PrimaryPercentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study

Dose-limiting toxicities were defined as obinutuzumab-related adverse events occurring within the first 28 days of each administration of obinutuzumab, with the exception of B-cell depletion and lymphopenia which are expected outcomes of treatment with obinutuzumab.

Time frame:
Baseline to 28 days after the last infusion of obinutuzumab (up to 6 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study
percentage of participants50/100 mg - Phase I, NHL100/200 mg - Phase I, NHL200/400 mg - Phase I, NHL400/800 mg - Phase I, NHL800/1200 mg - Phase I, NHL1200/2000 mg - Phase I, NHL1600/800 mg - Phase I, NHL400/800 mg - Phase I, CLL800/1200 mg - Phase I, CLL1200/2000 mg - Phase I, CLL1000/1000 mg - Phase I, CLL
Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study00000000000
PrimaryPercentage of Participants With Best Overall Response in Phase II of the Study

Best overall response (BOR) was defined as the percentage of participants with a complete response (CR) or partial response (PR)

Time frame:
by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response in Phase II of the Study
percentage of participants400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
Percentage of Participants With Best Overall Response in Phase II of the Study33.363.623.836.830.0
SecondaryPercentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study

A complete response was defined as the disappearance of all evidence of disease (NHL) and symptoms; normalization of biochemical abnormalities (NHL); regression of lymph nodes and nodal masses to normal size; decrease of nodes in the sum of the products of the greatest diameters (SPD); regression in size of the spleen and/or liver, should not be palpable, and disappearance of nodules related to lymphoma (CLL). Complete/unconfirmed (CRu) response includes NHL patients with one or more of the following: 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the SPD; 2) Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). Complete Response with Incomplete Bone Marrow Recovery (CRi) was measured only in patients with CLL.

Time frame:
by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR/CRu/CRi) in Phase II of the Study
percentage of participants400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
CR5.613.69.515.85.0
CRu5.69.14.80.0NA
CRiNANANANA0.0
SecondaryPercentage of Participants With Partial Response (PR) in Phase II of the Study

A PR was defined as a \>=50% decrease in SPD of the 6 largest nodes or nodal masses; no increase in size of other nodes, liver, or spleen; regression of splenic and hepatic nodules by \>=50% in their SPD or, for single nodules, in the long axis (CLL only); and no new disease sites.

Time frame:
by Cutoff Date: 31 March 2012 (within 3 years, 4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Partial Response (PR) in Phase II of the Study
percentage of participants400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
Percentage of Participants With Partial Response (PR) in Phase II of the Study22.240.99.521.125.0
SecondaryProgression-free Survival (PFS) in Phase II of the Study

PFS was defined as the time from start of treatment to disease progression (PD) or death due to any cause, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is positron emission tomography (PET)-positive with histological confirmation.

Time frame:
by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Reported as:
Median · days
Progression-free Survival (PFS) in Phase II of the Study
days400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
Progression-free Survival (PFS) in Phase II of the Study182 (106 to 526)361 (343 to 678)78 (42 to 260)83 (43 to 339)324 (217 to 357)
SecondaryDuration of Response by Disease Type in Phase II of the Study

Duration of complete response was defined as the time from the first complete or partial response until disease progression (PD) or death, whichever occurred first. For non-Hodgkin's lymphoma participants, PD was defined as \>= 50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for participants with a partial response or non-responders or the appearance of any new lesion during or at the end of therapy. For chronic lymphocytic leukemia participants, PD was defined as: (1) A \>= 50% increase from nadir in the SPD of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules); a lymph node with a short axis of \< 1.0 cm must increase by \>= 50% and to a size of 1.5×1.5 cm or \> 1.5 cm in the longest axis. (2) Appearance of any new lesion \> 1 cm in the short axis. (4) A new site that is PET-positive with histological confirmation.

Time frame:
by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Reported as:
Median · days
Duration of Response by Disease Type in Phase II of the Study
daysPhase II, iNHLPhase II, aNHLPhase II, CLL
Duration of Response by Disease Type in Phase II of the Study523 (23 to 952)298 (95 to 929)272.5 (23 to 794)
SecondaryParticipants With Event-Free Survival (EFS) in Phase II of the Study

EFS is defined as the time from start of treatment to disease progression/relapse, death or, in case of early withdrawal from the treatment period, the (end) date of last dose, whatever comes first.

Time frame:
by the end of the follow-up period in Phase II of the study (within 3 years, 4 months)
Reported as:
Number · participants
Participants With Event-Free Survival (EFS) in Phase II of the Study
participants400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
Participants With Event-Free Survival (EFS) in Phase II of the Study56234
SecondaryPharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study

B-cell depletion was defined in two ways: definition 1 - decrease below 5% baseline level and definition 2 - decrease below 0.04 x 109/L. B-cell recovery was defined in two ways: definition 1 - return to at least 50% of baseline level and definition 2 - return to at least 0.08 x 109/L.

Time frame:
by the end of Phase II (within 3 years, 4 months)
Reported as:
Number · participants
Pharmacodynamics: Participants With Peripheral B-cell Recovery After Having Had Depletion at End of Treatment During Phase II of the Study
participants400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLL
within 6 months (n=11,19,11,12,13)00003
within 9 months (n=8,17,6,5,10)00010
within 12 months (n=5,16,4,5,9)02103
within 18 months (n=4,13,3,3,8)01012
within 24 months (n=3,10,2,3,5)22102
after 24 months (n=3,4,1,2,0)10010
SecondaryPercentage of Retreated Participants With Response

Patients who might benefit from retreatment were allowed to be treated again at the request of the investigator.

Time frame:
by Cutoff Date: 25 November 2013 (within 4 years, 2 months)
Reported as:
Number · percentage of participants
Percentage of Retreated Participants With Response
percentage of participantsRetreated Participants
Best overall response62
Complete response23
Partial response38
SecondaryMaximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants

Obinutuzumab serum pharmacokinetic (PK) parameters in NHL participants following ascending doses.

Time frame:
at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
Reported as:
Geometric mean · µm/ml*day
Maximum Plasma Concentration (Cmax) of Obinutuzumab in NHL Participants
µm/ml*day400 mg - Phase I, NHL800 mg - Phase I, NHL1200 mg - Phase I, NHL2000 mg - Phase I, NHL
Cycle 1 Day 1 (n=4,6,6,0)134 ± 27.1234 ± 63.1307 ± 30.6NA ± NA
Cycle 1 Day 8 (n=0,4,6,6)NA ± NA367 ± 24.2449 ± 26.4714 ± 28.6
Cycle 8 (n=0,5,5,5)NA ± NA698 ± 65.41070 ± 62.61380 ± 66.1
SecondaryArea Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study

Blood samples were taken on Day 1 (pre-infusion, end of infusion, 3-6 hours post-infusion) of Cycle 1. Nonlinear mixed-effects modeling (with NONMEM software) was used to analyze the pooled samples for dose-concentration-time data of obinutuzumab.

Time frame:
Day 1 of Cycle 1
Reported as:
Geometric mean · µm/ml*day
Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study
µm/ml*day400 mg - Phase I, NHL800 mg - Phase I, NHL1200 mg - Phase I, NHL2000 mg - Phase I, NHL
Area Under the Concentration-time Curve of Obinutuzumab Administered on Day 1 of Cycle 1 in Phase I of the Study459 ± 64.7993 ± 30.51057 ± 60.5146 ± 49.6
Other pre-specifiedMaximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients
Time frame:
at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 8 (over 168 days)
Reported as:
Geometric mean · micrograms/mL
Maximum Plasma Concentration (Cmax) of Obinutuzumab in CLL Patients
micrograms/mL400 mg - Phase I, CLL800 mg - Phase I, CLL1200 mg - Phase I, CLL2000 mg - Phase I, CLL
Cycle 1 Day 1 (n=3,3,3,0)216 ± 34.1210 ± 74.0307 ± 21.4NA ± NA
Cycle 1 Day 8 (n=0,0,3,3)NA ± NANA ± NA437 ± 11.8735 ± 9.79
Cycle 8 (n=3,3,3,4)485 ± 48.1573 ± 73.2741 ± 32.81730 ± 32.6

Adverse events

Collected over Through final cut off in November 2013. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population—46/134 (34.3%)123/134 (91.8%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventSafety Population
Infusion related reactionInjury, poisoning and procedural complications8/134
Febrile neutropeniaBlood and lymphatic system disorders5/134
PyrexiaGeneral disorders4/134
Tumour lysis sydromeMetabolism and nutrition disorders4/134
AnaemiaBlood and lymphatic system disorders2/134
ThrombocytopeniaBlood and lymphatic system disorders2/134
Cardiac failureCardiac disorders2/134
Abdominal painGastrointestinal disorders2/134
Lung infectionInfections and infestations2/134
Aplasia pure red cellBlood and lymphatic system disorders1/134
Most frequent other events
Showing 10 of 24
Most frequent other events
EventSafety Population
Infusion related reactionInjury, poisoning and procedural complications107/134
AstheniaGeneral disorders35/134
DiarrhoeaGastrointestinal disorders23/134
LymphopeniaBlood and lymphatic system disorders19/134
CoughRespiratory, thoracic and mediastinal disorders19/134
AnaemiaBlood and lymphatic system disorders18/134
NeutropeniaBlood and lymphatic system disorders18/134
ThrombocytopeniaBlood and lymphatic system disorders15/134
BronchitisInfections and infestations15/134
NasopharyngitisInfections and infestations15/134

Baseline characteristics

Safety population: All enrolled participants who had received at least 1 dose of obinutuzumab.

Age, Categorical
Age, Categorical(Participants)50-2000 mg Phase I, NHL400-2000 mg Phase I, CLL400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLLTotal
<=18 years00000000
Between 18 and 65 years1171414671170
>=65 years106481512964
Sex: Female, Male
Sex: Female, Male(Participants)50-2000 mg Phase I, NHL400-2000 mg Phase I, CLL400/400 mg - Phase II, iNHL1600/800 mg - Phase II, iNHL400/400 mg - Phase II, aNHL1600/800 mg - Phase II, aNHL1000/1000 mg - Phase II, CLLTotal
Female1246985852
Male99121313141282
08

Study locations

16 sites
  • Creteil, 94010, France
  • Le Mans, 72015, France
  • Lille, 59037, France
  • Marseille, 13273, France
  • Montpellier, 34295, France
  • Nantes, 44093, France
  • Paris, 75475, France
  • Paris, 75651, France
  • Pessac, 33604, France
  • Pierre Benite, 69495, France
  • Rennes, 35033, France
  • Rouen, 76038, France
  • Toulouse, 31059, France
  • Tours, 37044, France
  • Vandoeuvre Les Nancy, 54511, France
  • Köln, 50924, Germany
09

References and documents

Publications

  • Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355 ↗
  • Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, Carlile DJ. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica. 2016 Feb;101(2):226-34. doi: 10.3324/haematol.2015.133421. Epub 2015 Dec 11. PubMed 26659915 ↗
  • Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. doi: 10.1182/blood-2014-07-586610. Epub 2014 Aug 20. PubMed 25143487 ↗
  • Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912-9. doi: 10.1200/JCO.2012.46.9585. Epub 2013 Jul 8. PubMed 23835718 ↗
  • Salles GA, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920-6. doi: 10.1200/JCO.2012.46.9718. Epub 2013 Jul 8. PubMed 23835715 ↗
  • Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. doi: 10.1182/blood-2012-01-404368. Epub 2012 Mar 19. PubMed 22431570 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2007
First posted
Aug 17, 2007
Start
Sep 2007
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Sep 22, 2015
Last update
Oct 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00517530
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 17, 2007
Start date
Sep 2007
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Sep 22, 2015
Last update
Oct 11, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion